Navigation Links
DaVita Acquires Majority Stake in HomeChoice Partners, Inc.

EL SEGUNDO, Calif., Sept. 10 /PRNewswire-FirstCall/ -- DaVita Inc. (NYSE: DVA) announced today that it has acquired 85% of the outstanding stock of HomeChoice Partners, Inc. for approximately $65 million in cash. HomeChoice, based in Norfolk, Virginia, provides a broad range of infusion therapy services to patients with acute or chronic conditions that can be treated at home or at an ambulatory infusion suite. HomeChoice has reported approximately $37 million in trailing twelve month revenue and currently serves over 2000 patients in Virginia, North Carolina, South Carolina and Georgia. The acquisition is expected to be EPS neutral in the first year.


The remaining 15% ownership interest will be retained by current HomeChoice senior management. This minority interest is subject to annual put and call options beginning 4 years from the date of closing.

"HomeChoice is a high quality company in a large and fragmented healthcare segment. It has an experienced management team that will fit well with DaVita's culture and our focus on outstanding clinical outcomes. We have modest initial growth plans, but as we learn the business we will evaluate the possibility for further investment in infusion services," said Kent Thiry, CEO of DaVita.

"HomeChoice is proud and excited to be part of a national healthcare company where the primary focus is to be the leader in patient outcomes. DaVita and HomeChoice are totally aligned in our goal to maintain that clinical leadership," said Mary Ann Cope, founder and President of HomeChoice.

This release contains forward-looking statements. Factors which could impact future results include the risk factors set forth in DaVita's SEC filings, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. The forward-looking statements should be considered in light of these risks and uncertainties. DaVita undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE DaVita Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Ossur Acquires the U.S. Orthopaedics Company
2. Stem of Hope: Stem Cell Research Acquires a Brittle Star As A model
3. Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug
4. Premier Army Hospital Acquires PET-CT Scanner
5. Wockhardt acquires Protinex, Farex brands from Netherland Co
6. Indoco Remedies Acquires La Nova Chem
7. Ranbaxy Acquires Glaxosmithklines Generic Unit in Spain
8. AIIMS Acquires Four-Armed Robot to Assist in Surgeries
9. Apollos Global Arm Acquires US-based Firm
10. ‘Obesity’ Acquires Permanent Resident Status in the US
11. Indias Wockhardt Acquires Irish Firm
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap ... and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s ... STEMI and Sepsis conditions present in similar ways and require time-critical intervention to avoid ...
(Date:11/26/2015)... ON and Cambridge, ON (PRWEB) , ... November ... ... today the availability of a real-time eReferral system for diagnostic imaging in the ... ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare ... participated in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was ... November 8th through Wednesday, November 11th, 2015. The conference was held at the ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... 2015 , ... Dr. John Pierce, Medical Director at the Ageless Forever clinic ... the Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, the Capillus272 ... need for surgery, prescription pills, or topical foams. , “Capillus272™ Pro is a ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology: